A look at the social media push for peptides as shortcuts to recovery and longevity, and the risks of doing it yourself.
Recap by typeshit. Full story at Blavity on MSN.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Patients who lost 10% or more of their starting weight on tirzepatide saw bigger gains across cardiometabolic markers, he notes.
A short explainer on Medicare coverage for Ozempic and similar weight loss drugs. Few details are given beyond the question itself, so tap through for the full answer.
Loading…